Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

9.190 +0.080 (+0.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,126,408
Open 8.900
Bid (Size) 9.100 (900)
Ask (Size) 9.260 (500)
Prev. Close 9.110
Today's Range 8.800 - 9.255
52wk Range 7.210 - 25.67
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA Biologics, Inc. – ADMA
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-48.6%
-48.6%
1 Month
-44.6%
-44.6%
3 Month
-49.6%
-49.6%
6 Month
-38.9%
-38.9%
1 Year
-52.7%
-52.7%

More News

Read More
News headline image
ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
From Kirby McInerney LLP
Via Business Wire
ADMA Biologics Inc (NASDAQ:ADMA) Reports Record 2025 Results Driven by ASCENIV, Provides 2026 Outlook ↗
Via Chartmill
News headline image
The Great Rotation of 2026: Why Small Caps are Finally Dethroning the Tech Giants
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law
From Bleichmar Fonti & Auld LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Why Are Shares Of ADMA Biologics Falling Today? ↗
Via Benzinga
Topics Stocks
News headline image
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ADMA Biologics Addresses Misleading Short-Seller Report
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
Via The Motley Fool
News headline image
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics (ADMA) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth ↗
Via The Motley Fool
Topics Energy
News headline image
Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
From ADMA Biologics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is ADMA Biologics Inc - Common Stock publicly traded?
Yes, ADMA Biologics Inc - Common Stock is publicly traded.
What exchange does ADMA Biologics Inc - Common Stock trade on?
ADMA Biologics Inc - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ADMA Biologics Inc - Common Stock?
The ticker symbol for ADMA Biologics Inc - Common Stock is ADMA on the Nasdaq Stock Market
What is the current price of ADMA Biologics Inc - Common Stock?
The current price of ADMA Biologics Inc - Common Stock is 9.190
When was ADMA Biologics Inc - Common Stock last traded?
The last trade of ADMA Biologics Inc - Common Stock was at 04/02/26 04:00 PM ET
What is the market capitalization of ADMA Biologics Inc - Common Stock?
The market capitalization of ADMA Biologics Inc - Common Stock is 1.80B
How many shares of ADMA Biologics Inc - Common Stock are outstanding?
ADMA Biologics Inc - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS